Last 22,040
Change Today +210.00 / 0.96%
Volume 537.9K
TEVA On Other Exchanges
New York
Tel Aviv
As of 10:24 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical ind ltd (TEVA) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/18/14 - $22,510
52 Week Low
12/24/13 - $13,560
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

teva pharmaceutical ind ltd (TEVA) Details

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Its products include Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim that stimulate the production of white blood cells; Lonquex, which reduces the duration of neutropenia and incidence of febrile neutropenia in adult patients; Eporatio that stimulates the production of red blood cells; and Synribo for chronic myeloid leukemia. In addition, it provides ProAir for the treatment of bronchospasm; QVAR for the treatment of asthma; Qnasl Nasal Aerosol for nasal allergy symptoms in adults; Plan B One-Step and Quartette, which prevents pregnancy; Seasonique and LoSeasonique that are extended-cycle oral contraceptives; Zoely, a regimen combination contraceptive oral pill; and ParaGard, a non-hormonal intrauterine contraceptive. Further, the company offers Enjuvia for vasomotor symptoms associated with menopause; hormone therapy treatments for menopause/perimenopause; therapies for infertility and urinary incontinence; and manufactures active pharmaceutical ingredients. It also distributes third party products. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

44,945 Employees
Last Reported Date: 02/10/14
Founded in 1901

teva pharmaceutical ind ltd (TEVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical ind ltd (TEVA) Key Developments

Teva Pharmaceuticals Announces Launch of 5mg Focalin XR Generic

Intellipharmaceutics International said that Teva Pharmaceuticals has launched the generic version of the 5mg strength of its dexmethylphenidate hydrochloride generic of Focalin XR(R). In addition, Intellipharmaceutics' manufacturing, marketing and distribution partner for Focalin XR generics in the US, Par Pharmaceutical, intends to launch this 5mg strength strength immediately upon the expiry of the exclusivity period six months after the date of launch of the 5mg strength by Teva.

Teva Pharmaceutical Industries Ltd. Announces Commercial Availability of Liquid Formulation of TREANDA (Bendamustine HCI) Injection

Teva Pharmaceutical Industries Ltd. announced the commercial availability of a liquid formulation of TREANDA (bendamustine HCI) Injection. This new liquid formulation removes the step of reconstituting lyophilized powder with sterile water prior to adding the required dose of medicine to the infusion bag and administering to a patient. By eliminating the need for reconstitution, preparation time for healthcare professionals is reduced. TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established. TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Teva Presents Positive Safety and Efficacy Data for QNASL (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis

Teva Pharmaceutical Industries Ltd. announced positive findings from a Phase III clinical study that examined the safety and efficacy of QNASL (beclomethasone dipropionate) Nasal Aerosol 80 g/day in children 4-11 years of age with perennial - or year round - allergic rhinitis (PAR). QNASL is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhinitis (SAR) in patients 12 years of age and older. On May 13, 2014, the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug application (sNDA) for a lower dose QNASL for the treatment of PAR and SAR in children 4-11 years of age. The submission was based on a comprehensive clinical development program consisting of three Phase III clinical trials designed to evaluate the safety and efficacy of QNASL 80 g/day in children with allergic rhinitis (AR). The 12-week, Phase III, randomized, double-blind, placebo-controlled, parallel-group clinical trial enrolled 547 patients ages 4 to 11 to receive two actuations (one 40 g/actuation per nostril) of QNASL or placebo nasal aerosol once daily. Symptoms were measured at 6 weeks and 12 weeks using average morning (AM) and evening (PM) reflective and instantaneous nasal symptom scores. Results indicate that patients treated with QNASL experienced a significantly greater improvement in PAR symptoms than patients treated with placebo. Overall, QNASL was well tolerated throughout the duration of the study with a safety profile comparable to placebo.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:IT 22,040.00 +210.00

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $68.70 USD +0.64
Actavis plc $270.47 USD +0.16
Baxter International Inc $72.40 USD -0.04
Eli Lilly & Co $67.32 USD +0.47
Valeant Pharmaceuticals International Inc C$162.67 CAD -0.18
View Industry Companies

Industry Analysis


Industry Average

Valuation TEVA Industry Range
Price/Earnings 17.6x
Price/Sales 2.4x
Price/Book 2.0x
Price/Cash Flow 19.7x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL IND LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at